Eisai Co. Ltd (EII F) stock market data APIs
€24.9436
0.37(1.5%)
as of October 31, 2025
Try our APIs with
free plan!
Eisai Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. The company offers Dayvigo, an orexin receptor antagonist for the treatment of insomnia; LEQEMBI, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody for Alzheimer's disease; Lenvima, an orally available multiple receptor tyrosine kinase inhibitor for the treatment of thyroid cancer and hepatocellular carcinoma, thymic carcinoma, renal cell carcinoma, and endometrial carcinoma; Fycompa, an anti-epileptic agent for primary generalized tonic-clonic seizures; and Halaven, a microtubule dynamics inhibitor for breast cancer and liposarcoma. It operates in Japan, China, the Americas, Europe, the Middle East, Africa, and East Asia Global South. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Prev. Close
24.9436
Open
25.3176
High
25.3176
Low
24.9436
52 wk Range
-51.13-33.8098
Market Cap
7 215 M
P/E Ratio
27.3043
Shares Outstanding
282 M
Revenue
803 022 M
Dividends (Yield)
0.0383
Beta
-0.182
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eisai Co. Ltd data using free add-ons & libraries
Get Eisai Co. Ltd Fundamental Data
Eisai Co. Ltd Fundamental data includes:
- Net Revenue: 803 022 M
- EBITDA: 101 172 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 30.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eisai Co. Ltd News
New
Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem
Two of Biogen's key growth drivers hit snags in the third-quarter. But Biogen stock yo-yoed and, most recently, edged down slightly. Continue Reading View Comments
Sector Update: Health Care Stocks Flat to Higher Premarket Thursday
Health care stocks were flat to higher premarket Thursday, with the iShares Biotechnology ETF (IBB) PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
STOCKHOLM, Oct. 30, 2025 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with...
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
RAHWAY, N.J. & NUTLEY, N.J., October 29, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-012 tri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
